Crizotinib is an oral-administered multitargeted small molecule tyrosine kinase inhibitor, which inhibits mesenchymal epithelial transition growth factor (c-MET) as well as ALK phosphorylation that is recommended as a first-line treatment option for patients with locally advanced or metastatic NSCLC who have the ALK gene rearrangement [3]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.